Skip to search formSkip to main contentSkip to account menu

5 ML daratumumab 20 MG/ML Injection [Darzalex]

Known as: 5 ML Darzalex 20 MG/ML Injection, Darzalex 100 MG per 5 ML Injection, DARZALEX 100 MG in 5 ML Injection 
National Institutes of Health

Related topics

Related topics

8 relations
DarzalexInjectionMannitolPolysorbate 20

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Daratumumab (▼ Darzalex): riesgo de reactivación del virus de la hepatitis B
2019
2019
Daratumumab (▼Darzalex®): riesgo de reactivación del virus de la hepatitis B
Review
2019
Review
2019
Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Intravenous daratumumab (DARZALEX®) is a human CD38 monoclonal antibody approved as combination therapy (with bortezomib… 
2018
2018
Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma
Multiple myeloma (MM) is a disease characterised by the neoplastic proliferation of plasma cells in the bone marrow, often… 
2018
2018
Besonders tiefes Ansprechen in der Zweitlinie
In der Behandlung des Multiplen Myeloms (MM) hat sich die Therapielandschaft in den letzten Jahren durch die Einfuhrung… 
Review
2017
Review
2017
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
Intravenous daratumumab (DARZALEX®) is a first-in-class human IgG1κ monoclonal antibody against CD38 available for use in… 
Review
2016
Review
2016
Daratumumab: First Global Approval
Daratumumab (Darzalex™) is a first-in-class, humanized IgG1κ monoclonal antibody that targets the CD38 epitope and was developed… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)